International Journal of Endocrinology and Metabolism

Published by: Kowsar

Effects of Raloxifene on Bone in Patients With Type 2 Diabetes

Itsuo Gorai 1 , *
Author Information
1 Department of Obstetrics and Gynecology, Hori Hospital, Futatsubashi-Cho, Seya-ku, Yokohama, Japan
Article information
  • International Journal of Endocrinology and Metabolism: September 01, 2012, 10 (4); 646-647
  • Published Online: September 5, 2012
  • Article Type: Letter
  • Received: May 28, 2012
  • Revised: May 29, 2012
  • Accepted: May 29, 2012
  • DOI: 10.5812/ijem.6558

To Cite: Gorai I. Effects of Raloxifene on Bone in Patients With Type 2 Diabetes, Int J Endocrinol Metab. 2012 ; 10(4):646-647. doi: 10.5812/ijem.6558.

Copyright © 2012, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 2006; 21(5): 765-71[DOI][PubMed]
  • 2. Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012; 10(2): 464-9[DOI]
  • 3. Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab. 2012; 30(3): 349-58[DOI][PubMed]
  • 4. Oleksik A, Duong T, Popp-Snijders C, Pliester N, Asma G, Lips P. Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis. Clin Endocrinol (Oxf). 2001; 54(5): 575-82[DOI][PubMed]
  • 5. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003; 88(3): 1174-8[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments